1. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
- Author
-
Guillaume Beaudoin-Bussière, Nick Daneman, Kent Cadogan Lofstgard, Damon C. Scales, Ryan Zarychanski, Na Li, Renée Bazin, Caroline Gabe, Yang Liu, Jeannot Dumaresq, Philippe Bégin, Lisa Schwartz, Richard Carl, Nadine Shehata, Nancy M. Heddle, Marshall J. Glesby, Alexis F. Turgeon, Heidi Wood, Bruce S. Sachais, Dean Ferguson, Allan Tinmouth, Dana V. Devine, Erin Jamula, Jeannie Callum, Andrés Finzi, Nancy Robitaille, Michaël Chassé, Melissa M. Cushing, Michelle P. Zeller, Luiz Amorim, Richard J. Cook, Donald M. Arnold, and Allison McGeer
- Subjects
medicine.medical_specialty ,biology ,business.industry ,medicine.medical_treatment ,Therapeutic effect ,Logistic regression ,Confidence interval ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,Relative risk ,biology.protein ,Medicine ,Intubation ,Antibody ,business ,Adverse effect - Abstract
The efficacy of convalescent plasma for COVID-19 is unclear. While most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content may influence patient outcomes.We conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 days of respiratory symptom onset. Patients were allocated 2:1 to 500 mL of convalescent plasma or standard of care. The composite primary outcome was intubation or death by 30 days. The effect of convalescent plasma antibodies on the primary outcome was assessed by logistic regression.The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility. 940 patients were randomized and 921 patients were included in the intent-to-treat analysis. Intubation or death occurred in 199/614 (32.4%) in the convalescent plasma arm and 86/307 (28.0%) in the standard of care arm; relative risk (RR) 1.16 (95% confidence interval (CI) 0.94-1.43; p=0.18). Patients in the convalescent plasma arm had more serious adverse events (33.4% vs. 26.4%; RR=1.27, 95% CI 1.02-1.57, p=0.034). The antibody content significantly modulated the therapeutic effect of convalescent plasma. In multivariate analysis, each standard log increase in neutralization or antibody-dependent cellular cytotoxicity independently reduced the potential harmful effect of plasma (OR=0.74; 0.57-0.95 and OR=0.66; 0.50-0.87, respectively), while IgG against the full transmembrane Spike protein increased it (OR=1.53, 95% CI 1.14-2.05).Convalescent plasma did not reduce the risk of intubation or death at 30 days among hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavourable antibody profiles may be associated with worse clinical outcomes compared to standard care.Trial registrationCONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1); NCT04348656; https://www.clinicaltrials.gov/ct2/show/NCT04348656
- Published
- 2021